Lactobacillus paracasei DG for Diverticular Disease Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diverticular disease fail to effectively control inflammatory processes in the colon, leading to persistent symptoms and complications such as diverticulitis, with a significant role of inflammation and dysbiosis in disease progression.
Innovation Solution
The use of probiotics comprising Lactobacillus paracasei DG CNCM I-1572 to down-regulate iNOS expression and pro-inflammatory cytokines, reducing inflammation and symptoms associated with diverticular disease, particularly in subjects with Symptomatic Uncomplicated Diverticular Disease preceded by Acute Diverticulis (SUDD+AD).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for diverticular disease are used, then structural modifications of the colon wall are addressed, but inflammatory processes in the colon are not effectively controlled
Solution Approach 1:
The probiotic Lactobacillus paracasei DG acts as an intermediary organism that modulates the inflammatory response in the colon. It interacts with the host immune system and intestinal microbiota to reduce pro-inflammatory cytokines and iNOS expression, thereby controlling inflammation without directly targeting the structural diverticula themselves.
Solution Approach 2:
The treatment changes the biological parameters of the colon environment by introducing probiotic bacteria that alter the expression levels of inflammatory markers. Specifically, it down-regulates iNOS expression and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), transforming the inflammatory state from persistent to controlled.
2Ease of operation
If probiotics are used to down-regulate inflammation, then symptoms are reduced, but the specific mechanism involves down-regulating iNOS expression and pro-inflammatory cytokines
Solution Approach 1:
The probiotic Lactobacillus paracasei DG performs multiple functions simultaneously: it colonizes the intestine, competes with pathogenic bacteria, modulates immune responses, and down-regulates multiple inflammatory markers (iNOS, TNF-α, IL-1β, IL-6). This multi-functional approach simplifies the treatment strategy while addressing the complex inflammatory mechanism through a single probiotic agent.
Data Source
Figure 1A~1C
Figure 2A~2C
Figure 3A~3D
AI summary
The present invention relates to the use of probiotics to control the inflammatory process of the colon in subjects with structural modifications of the colon wall, preferably in subjects with diverticulosis, and affected by diverticular disease.